JAKARTA. PT Hetzer Medical Indonesia Tbk (MEDS), a manufacturer and supplier of medical devices making its debut on Indonesia Stock Exchange (IDX) in 2022, suffered another loss of IDR 3.69 billion in the second quarter (Q2) of 2024.

Said loss resulted from MEDS’s revenue that only reached IDR 5.44 billion, slipping 25% year-on-year (yoy) or from the same quarter last year. However, compared to Q1 2024, its sales actually increased 12.4%.

For the record, MEDS also reported a loss of IDR 927.73 million in Q1 2024. Then, in 2023, its loss worsened to IDR 3.57 billion.

According to the recently issued financial statement, MEDS’s sales in Q2 2024 came from mask products worth IDR 1.23 billion and mask plus products of IDR 1.82 billion. Then, tensimeter sales brought in IDR 1.78 billion, followed by stethoscope sales of IDR 428 million, bouffant cap of IDR 166 million, and antiseptic products of IDR 2.5 million.

MEDS’s mask sales were corrected quite heavily, by 78.9% yoy, from IDR 5.85 billion seen in Q2 2023. Thankfully, mask plus sales increased 53% yoy.

According to IDNFinancials data, MEDS debuted on IDX on August 10, 2022. Its IPO raised IDR 39.06 billion from issuing 312.5 million shares to the public. (KR/ZH)